Accueil / Communiqués / Nanobiotechnologies: 2019 Applications, Markets & Companies; Forecast to 2028 with Profiles for 252 Companies –

Nanobiotechnologies: 2019 Applications, Markets & Companies; Forecast to 2028 with Profiles for 252 Companies –

Monday, February 4th 2019 at 10:20am UTC

DUBLIN–(BUSINESS WIRE)– The « Nanobiotechnologies-
Applications, Markets & Companies »
report from Jain
PharmaBiotech has been added to’s

The report starts with an introduction to various techniques and
materials that are relevant to nanobiotechnology. It includes some of
the physical forms of energy such as nanolasers. Some of the
technologies are scaling down such as microfluidics to nanofluidic
biochips and others are constructions from bottom up. Application in
life sciences research, particularly at the cell level sets the stage
for role of nanobiotechnology in healthcare in subsequent chapters.

Some of the earliest applications are in molecular diagnostics.
Nanoparticles, particularly quantum dots, are playing important roles.
In vitro diagnostics, does not have any of the safety concerns
associated with the fate of nanoparticles introduced into the human
body. Numerous nanodevices and nanosystems for sequencing single
molecules of DNA are feasible. Various nanodiagnostics that have been
reviewed will improve the sensitivity and extend the present limits of
molecular diagnostics.

An increasing use of nanobiotechnology by the pharmaceutical and
biotechnology industries is anticipated. Nanotechnology will be applied
at all stages of drug development – from formulations for optimal
delivery to diagnostic applications in clinical trials. Many of the
assays based on nanobiotechnology will enable high-throughput screening.
Some of nanostructures such as fullerenes are themselves drug candidates
as they allow precise grafting of active chemical groups in
three-dimensional orientations.

The most important pharmaceutical applications are in drug delivery.
Apart from offering a solution to solubility problems, nanobiotechnology
provides and intracellular delivery possibilities. Skin penetration is
improved in transdermal drug delivery. A particularly effective
application is as nonviral gene therapy vectors. Nanotechnology has the
potential to provide controlled release devices with autonomous
operation guided by the needs.

Nanomedicine is now within the realm of reality starting with
nanodiagnostics and drug delivery facilitated by nanobiotechnology.
Miniature devices such as nanorobots could carry out integrated
diagnosis and therapy by refined and minimally invasive procedures,
nanosurgery, as an alternative to crude surgery. Applications of
nanobiotechnology are described according to various therapeutic
systems. Nanotechnology will markedly improve the implants and tissue
engineering approaches as well.

Of the over 1,000 clinical trials of nanomedicines, approximately 100
are selected and tabulated in major therapeutic areas. Other
applications such as for management of biological warfare injuries and
poisoning are included. Contribution of nanobiotechnology to nutrition
and public health such as supply of purified water are also included.

There is some concern about the safety of nanoparticles introduced in
the human body and released into the environment. Research is underway
to address these issues. As yet there are no FDA directives to regulate
nanobiotechnology but as products are ready to enter market, these are
expected to be in place.

Future nanobiotechnology markets are calculated on the basis of the
background markets in the areas of application and the share of this
market by new technologies and state of development at any given year in
the future. This is based on a comprehensive and thorough review of the
current status of nanobiotechnology, research work in progress and
anticipated progress.

There is definite indication of large growth of the market but it will
be uneven and cannot be plotted as a steady growth curve. Marketing
estimates are given according to areas of application, technologies and
geographical distribution starting with 2018. The largest expansion is
expected between the years 2023 and 2028.

Profiles of 252 companies, out of over 500 involved in this area, are
included in the last chapter along with their 185 collaborations. The
report is supplemented with 51 Tables, 32 figures and 800 references to
the literature.

Topics Covered

Executive Summary

1. Introduction

2. Nanotechnologies

3. Nanotechnologies for Basic Research Relevant to Medicine

4. Nanomolecular Diagnostics

5. Nanopharmaceuticals

6. Role of Nanotechnology in Biological Therapies

7. Nanodevices & Techniques for Clinical Applications

8. Nanooncology

9. Nanoneurology

10. Nanocardiology

11. Nanopulmonology

12. Nanoorthopedics

13. Nanoophthalmology

14. Nanomicrobiology

15. Miscellaneous Healthcare Applications of Nanobiotechnology

16. Nanobiotechnology and Personalized Medicine

17. Nanotoxicology

18. Ethical and Regulatory Aspects of Nanomedicine

19. Research and Future of Nanomedicine

20. Nanobiotechnology Markets

21. References

22. Nanobiotech Companies

For more information about this report visit

Laura Wood, Senior Press Manager

E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900

Source: Research and Markets

Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …